What’s Hot: Don’t let the bedbugs bite
CHICAGO —In addition to sunblock and the trial-sized shampoo and conditioner, retailers can add bedbug spray to the list of “must haves” they’ll be offering consumers who travel.
Bedbugs are making a comeback, and have been increasingly turning up in hotels across the country. In a survey of 700 mid-priced hotels, 25% were infested. The parasites also are finding their way to dorm rooms.
Most active during the warm months of the peak travel season, from April to October, bedbugs can hitch a ride in luggage and infest a traveler’s home, said Bruce Brenner, COO of RMB Group, the manufacturer of Rest Easy bedbug spray.
Rest Easy, an all-natural spray made from essential oils, can keep the bugs at bay. The spray, which can be used on bedding, luggage and furniture, contains no pesticides or chemicals, but is effective in keeping bedbugs from hitching a ride home with travelers.
The spray is available in 2-oz. twin packs for a suggested $6.99 retail, and a 16-oz. trigger spray, which retails for $9.99. A 24-unit counter display is available for the 2-oz. twin packs, and Brenner said the company will work with retailers on in-and-out merchandising units.
Hy-Vee celebrates the other white meat
WEST DES MOINES, Iowa A lot of people complain about pork barrel spending, but not Midwest supermarket chain Hy-Vee.
October is National Pork Month, and the West Des Moines, Iowa-based Hy-Vee announced Friday that sales of the meat have increased more than 25% over October 2008. The chain said it was on track to increase pork tonnage by more than 30%.
“With pork prices the lowest they’ve been in more than a decade, we’ve focused our marketing efforts on promoting pork as a great value for consumers,” Hy-Vee assistant VP meat operations Kenan Judge said in a statement. “Today’s shopper is looking for nutritious, economical meal ideas, and pork perfectly fits the bill.”
Patients prefer new diabetes drug Victoza over its competitor, survey finds
MONTREAL A new diabetes drug satisfied patients more than its competitor, according to a study funded by the drug’s manufacturer.
According to data on 379 patients who took the Diabetes Treatment Satisfaction Questionnaires, presented Thursday at the 20th World Diabetes Congress and published in medical journal The Lancet, patients taking Novo Nordisk’s drug Victoza (liraglutide) perceived less abnormally low or high blood sugar levels — known respectively as hypoglycemia and hyperglycemia — than those taking Byetta (exenatide), made by Eli Lilly & Co., Amylin Corp. and Alkermes.
Victoza is approved in Europe, but Novo Nordisk is still waiting for approval from the Food and Drug Administration in the United States.
“Liraglutide has shown here in a convincing study that it is associated with less nausea, less perceived hypoglycemia and definitely higher patient satisfaction compared to exenatide,” principal investigator Wolfgang Schmidt said in a statement. “Patient-reported outcomes data is an important extension of the efficacy data. If a patient is satisfied with his or her treatment, then they are much more likely to really stick to the treatment over the long term, which is necessary in Type 2 diabetes.”